Education
About Us
Working with TipRanks
Follow Us
Biotricity Inc (BTCY)
OTHER OTC:BTCY
Top Page
Biotricity
(OTC:BTCY)
Rating:45Neutral
Price Target:―
Positive Factors
Financial Performance
Biotricity reported a doubling of free cash flow on an 11% increase in sales to $3.6M, highlighting improved financial performance.
Product Innovation
Product innovation remains a catalyst as the next-generation, cellular-enabled Biocore Pro gains traction, extending Biotricity's market reach.
Strategic Partnerships
Biotricity's partnerships with top group purchasing organizations and specialist organizations are gaining traction, offering new opportunities for product adoption.
Negative Factors
Market Risks
An investment in Biotricity is subject to risks such as dilution and competition against companies with greater resources.
Small-Cap Challenges
Investment in Biotricity carries risks common to small-cap companies, including end-market product acceptance and pricing challenges.
Biotricity (BTCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.08M
Dividend YieldN/A
Average Volume (3M)41.70K
Price to Earnings (P/E)―
Beta (1Y)-0.36
Revenue Growth14.09%
EPS Growth38.18%
CountryUS
Employees55
SectorHealthcare
Sector Strength37
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.08
Shares Outstanding26,567,768
10 Day Avg. Volume41,797
30 Day Avg. Volume41,700
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.53
P/FCF Ratio-3.07
Enterprise Value/Market Cap2.82
Enterprise Value/Revenue2.47
Enterprise Value/Gross Profit3.23
Enterprise Value/Ebitda-10.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Biotricity Business Overview & Revenue Model
Company DescriptionBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
How the Company Makes MoneyBiotricity makes money through the sale and leasing of its medical devices, primarily the Bioflux device, to healthcare providers, including hospitals and clinics. Revenue is generated from both the initial sale/lease of the device and ongoing service fees for data monitoring and analysis. The company may also engage in partnerships with healthcare organizations to expand its reach and enhance service offerings. Additionally, Biotricity may explore revenue opportunities through research and development collaborations in the medical technology sector.
Biotricity Earnings Call Summary
Earnings Call Date:Jul 17, 2025
(Q4-2025)
| % Change Since: 23.68%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in strategic partnerships, market expansion, and financial performance, including revenue growth and positive adjusted EBITDA. However, despite these achievements, the company still faced a net loss, and the long sales cycles may delay future revenue gains.Q4-2025 Updates
Positive Updates
Expansion of Cardiac AI Cloud Platform
Biotricity expanded its Cardiac AI cloud platform, leveraging over 1 trillion heartbeats of anonymized data, and partnered with Amazon AWS and Google's TensorFlow to enhance diagnostic accuracy and patient outcomes.
Strategic Partnerships and Market Reach
Biotricity formed alliances with three top GPOs, accessing 90% of US hospitals, and received approvals in Canada and Saudi Arabia, expanding its market reach.
Revenue and Profit Growth
For the fourth quarter, revenue increased by 16.5% year-over-year to $3.7 million, and for the fiscal year, revenue rose by 14.3% to $13.8 million. Gross profit improved by 31%, and operating expenses decreased by 24.5%.
Positive Adjusted EBITDA
Achieved positive adjusted EBITDA of $438,000 in the last quarter of fiscal 2025, marking a significant milestone towards profitability.
Launch of HeartSecure Service
Biotricity launched HeartSecure, a direct-to-consumer heart health screening service, targeting the $1.1 billion home heart health market.
Negative Updates
Net Loss Despite Revenue Growth
Net loss attributable to common stockholders for the fiscal year ended March 31, 2025, was $11.9 million, although it improved from the previous year's $14.9 million loss.
Long Sales Cycles and Rollout Periods
Sales cycles and rollout periods for new partnerships, particularly with GPOs, are lengthy, potentially delaying revenue realization.
Company Guidance
In the recent earnings call, Biotricity provided guidance on its fiscal year 2025 performance, highlighting revenue growth, strategic partnerships, and advancements in technology. The company reported a 16.5% year-over-year revenue increase for the fourth quarter, reaching $3.7 million, and an annual revenue rise of 14.3% to $13.8 million. Their gross profit for the quarter rose by 31% to $3 million, with a gross margin improvement to 80.4%. Operating expenses decreased by 24.5% to $13 million for the fiscal year, with significant reductions in SG&A and R&D expenses. The call emphasized Biotricity's progress toward profitability and positive adjusted EBITDA, which reached $438,000 in the last quarter. The company's strategic focus on expanding its Cardiac AI cloud platform and securing FDA clearance for its AI clinical model aims to enhance diagnostic accuracy and patient outcomes. Additionally, international market expansions, including regulatory approval in Canada and Saudi Arabia, are expected to contribute to future revenue growth.Biotricity Financial Statement Overview
Summary
Biotricity demonstrates robust revenue growth but struggles with profitability and financial stability. The high debt levels and negative equity raise concerns about long-term sustainability. While the company is expanding its top line, achieving profitability and strengthening the balance sheet are critical for future resilience.Income Statement
Biotricity shows a positive revenue growth trend with a 37.6% increase from 2023 to 2024 (TTM), indicating strong top-line expansion. However, the company faces substantial profitability challenges with persistently negative EBIT and net profit margins, reflecting ongoing operational inefficiencies and high costs relative to revenues.45
Neutral
Balance Sheet
The company's balance sheet reveals considerable financial strain. With a negative stockholders' equity and a high debt-to-equity ratio, Biotricity is highly leveraged, indicating potential solvency issues. The equity ratio is also negative, further highlighting financial instability and risk.30
Negative
Cash Flow
Biotricity's cash flow statement shows negative free cash flow, though there is a slight improvement in operating cash flow from previous periods. The operating cash flow to net income ratio is negative, suggesting cash generation challenges. However, positive financing cash flows indicate reliance on external funding to support operations.40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.79M | 13.79M | 12.06M | 9.64M | 7.65M | 3.38M |
| Gross Profit | 10.56M | 10.56M | 8.36M | 5.44M | 4.57M | 1.27M |
| EBITDA | -3.21M | -3.21M | -8.90M | -15.40M | -18.02M | -13.35M |
| Net Income | -8.42M | -8.42M | -14.09M | -18.66M | -29.13M | -15.49M |
Balance Sheet | ||||||
| Total Assets | 5.64M | 5.64M | 5.94M | 6.51M | 16.68M | 4.44M |
| Cash, Cash Equivalents and Short-Term Investments | 365.14K | 365.14K | 786.06K | 570.46K | 12.07M | 2.20M |
| Total Debt | 26.09M | 26.09M | 23.88M | 19.55M | 15.35M | 4.71M |
| Total Liabilities | 35.66M | 35.66M | 35.92M | 26.36M | 18.82M | 11.27M |
| Stockholders Equity | -30.01M | -30.01M | -29.98M | -19.85M | -2.14M | -6.83M |
Cash Flow | ||||||
| Free Cash Flow | -2.38M | -2.38M | -6.69M | -13.55M | -15.19M | -11.08M |
| Operating Cash Flow | -2.38M | -2.38M | -6.69M | -13.55M | -15.16M | -11.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -29.77K | 0.00 |
| Financing Cash Flow | 1.93M | 1.93M | 6.74M | 2.00M | 25.17M | 12.20M |
Biotricity Technical Analysis
Positive
0.47
Price Trends
0.45
Positive
0.44
Positive
0.42
Positive
Market Momentum
<0.01
Negative
54.19
Neutral
82.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTCY, the sentiment is Positive. The current price of 0.47 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.45, and above the 200-day MA of 0.42, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.19 is Neutral, neither overbought nor oversold. The STOCH value of 82.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BTCY.
Biotricity Risk Analysis
Biotricity disclosed 49 risk factors in its most recent earnings report. Biotricity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biotricity Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.39B | 0.36 | -62.86% | 2.36% | 15.48% | -2.68% | |
49 Neutral | $8.02M | ― | -72.70% | ― | 5.05% | 26.13% | |
48 Neutral | $7.97M | ― | -151.23% | ― | 3.30% | 31.84% | |
46 Neutral | $8.47M | 0.66 | -499.57% | ― | -33.92% | ― | |
45 Neutral | $12.08M | ― | 42.40% | ― | 14.09% | 38.18% | |
45 Neutral | $9.43M | ― | -45.38% | ― | -48.61% | 32.18% | |
41 Neutral | $8.47M | ― | -56.80% | ― | -91.22% | 11.84% |
* Healthcare Sector Average
Performance Comparison
BTCY
Biotricity
0.47
-0.02
-4.08%
SSKN
Strata Skin Sciences
1.91
-1.11
-36.75%
NURO
Neurometrix
4.58
1.60
53.69%
BMRA
Biomerica
3.11
0.72
30.13%
CODX
Co-Diagnostics
0.25
-0.77
-75.49%
PAVM
PAVmed
0.41
-0.39
-48.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.